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Cells are complex machines that sometimes get out of control and take over their host,i.e., become cancer cells. It goes without saying that to control or repair them, a
thorough understanding of how they work and a specific understanding of what has gone
awry is required. The study by Chen et al.,1 led by one of the pioneers in this field, is a
technically rigorous step toward sorting these errant machines into broad categories that
may require different therapeutic approaches. In this study, Chen et al. defined a predictor
of survival based on data from 680 tumors and defined a clinically feasible reverse
transcriptase polymerase chain reaction classifier that significantly classified a test set of
tumors for survival. It is thus a significant study for the size of the training set, the rigor
of the analysis, and the translation to a reverse transcriptase polymerase chain reaction
assay in a 101-patient test set. Such classification attempts, and in particular attempting to
understand what these classifications imply for patient management, are clearly the next
frontier in oncology. The last sentence of the abstract looks toward clinical application and
states that these data should be incorporated “into new clinical trials with the goal of
personalized treatment of lung cancer patients and improving patient survival.” For
example, the discovery and definition of subsets of these tumors driven by epidermal
growth factor receptor (EGFR) mutations and ALK fusions have revolutionized both our
understanding of how cancers work and our therapies for these subsets.
Definition of clinically actionable subsets by expression array technology, as
described in the article, has to date been much less successful, at least in part because of
two significant issues: (1) they are typically tied to a particular way of looking at the
cancer cell, ignoring all others, and (2) they fail to carefully define the clinical problem
they are addressing and choose sample sets and analyses appropriate to answer this
question rather than whatever is conveniently available. This study, although far from
unique in this respect, suffers from both these issues.
Regarding the first problem, it is now clear that cancer cells are not completely
defined and cannot be completely understood by studying their pattern of acquired genetic
mutations or by studying RNA expression patterns in isolation. EGFR-mutant tumors are
clearly different from EGFR wild-type tumors in almost every way—patients with these
tumors on average live longer no matter how you treat them, respond better to chemo-
therapy, and have different patterns of relapse and metastasis. There are a handful of
mutant genes known today (perhaps about 10) that logically define significant subsets of
lung cancers, and future studies attempting to define RNA expression classifiers should
include these gene mutation variables in their analyses. Important RNA patterns associ-
ated with a clinical phenotype might be completely different in each of these gene
mutation subsets, and by mixing these all together in the training set, we unnecessarily
muddle our data. Although “multidimensional” classification analytic techniques need to
be optimized, it is clear that future classification studies should take into account at least
these dominant subsets. This study does not do this, even lumping adenocarcinomas with
squamous carcinomas, each with clear differences in gene mutation patterns. Conversely,
it is also clear that all tumors with EGFR mutations, and even all tumors with exactly the
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same EGFR mutation, do not behave alike, and thus RNA
expression classifiers may help define different behaviors
within these genetic subsets.
The second problem is as important and perhaps more
subtle but just as pervasive. To answer a question, the
question must be clearly defined, and one must use well-
defined and appropriate datasets to find useful answers. The
goal of this study is to define a “prognostic” classifier (often
defined as outcome independent of therapy) and not a “pre-
dictive” one (defining which patients will benefit from ther-
apy). However, it is very important to define the projected use
of such a “prognostic” classifier. It is stated in the Introduc-
tion of the article that such risk classifiers are useful in
defining patients destined to relapse and thus might benefit
from adjuvant therapy. Adjuvant chemotherapy clearly im-
proves survival, and adjuvant radiation clearly alters the risk
of local relapse. Thus, ideally, clinically useful prognostic
classifications should assist in the definition of a subset of
patients who are at high risk for relapse without adjuvant
therapy, and within this subset, there are hopefully tumors,
defined by a predictive classifier, that become low risk when
treated with adjuvant chemotherapy or radiation.
Therefore, for this purpose, this prognostic classifier
should have been derived only using patients who received no
adjuvant therapy. The inclusion of patients who received
adjuvant therapy into the training set dooms the results to
failure in this regard. Specifically, individual patients at high
risk of relapse without adjuvant therapy, but who benefited
from adjuvant therapy and became low risk (did not relapse)
because of it, would be falsely forced into the low-risk group
of patients by this approach. Resulting classifiers would only
identify patients who do poorly and don’t do any better with
adjuvant therapy. The subset analysis presented in the article
showed that after definition of this classifier, high-risk patients
showed no benefit from adjuvant chemotherapy, which confirms
this problem. If the question is definition of mechanisms driving
relapse, active pathways in untreated patients who relapse
should be compared with untreated patients who don’t, and this
may define novel therapy targets that may alter this behavior.
The use of patients homogeneous for the relevant clin-
ical questions is thus absolutely essential. Many of the pa-
tients in this study had “unknown” adjuvant treatments.
Samples with incomplete clinical annotation should not be
included at all in any modern analysis, and treated patients
should not be lumped with untreated ones, if the intent is to
identify patients at risk for relapse and who might benefit
from these therapies. The era of definition of classifiers using
“samples of convenience” accumulated for the purpose of
large numbers and good p values should end.
Although difficult, accounting for the major genetic
subsets in expression array studies, defining the exact ques-
tion being asked, and using appropriate clinical cohorts
should be expected today. As our state of knowledge pro-
gresses, the general approach to defining broad categories of
tumors that behave more or less alike with only moderate
degrees of certainty will hopefully give way to a day when
tumors are characterized by possibly dozens of potently
predictive patterns of inherited differences, acquired muta-
tions, altered gene and protein expression, post-translational
modifications, and signaling patterns, with therapies designed
to match each pattern. We need to stop treating lung cancer as
a single disease at all levels of analysis and clearly define our
clinical goals when designing our research experiments.
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Response:
Dr. David Carbone makes several points on our man-
uscript which he feels are problematic and suggests clinical-
ly-actionable subsets by expression array technology, as de-
scribed in our paper are not successful because: 1) they are
typically tied to a particular way of looking at the cancer cell,
ignoring all others, and 2) they fail to carefully define the
clinical problem they are addressing and choose sample sets
and analyses appropriate to answer this question rather than
whatever is conveniently available. Although we do not agree
with his conclusions, we think they are interesting and im-
portant issues and we welcome the opportunity to discuss
them. As detailed in our manuscript by Chen et al, we
hypothesized that there are diverse survival-related processes
that are associated with lung adenocarcinomas and we then
actively attempted to incorporate this heterogeneity into a
model by using representation of small numbers of genes
from as many diverse survival-related clusters (presumably
cell processes) as possible. This is in contrast to many models
where the most significant survival-related genes are used
regardless of whether they are associated with the same
underlying biological process or not. Our goal was to develop
a model that was broadly useable for a diverse tumor popu-
lation such as that seen in lung adenocarcinomas and where
we as yet do not know all of the processes that are critical for
defining patient outcome. While we do not disagree with his
comments regarding ALK fusions or EGFR-mutant lung
adenocarcinomas, these tumors which are from non-smokers
are clearly genomically more stable, and quite unlike the vast
majority of lung cancers. In fact, Dr. Carbone admits that
there are a handful of genes that may significantly define
subsets; we humbly submit that these form a small slice of the
pie which are defined by complex alterations in multiple
pathways. Although it is tempting to hope that gene muta-
tions will clearly define other subgroups as Dr. Carbone
suggests, analyses done with our collaborators (Ding et al,
Nature, 2008) reveal that lung adenocarcinomas often have
very large numbers of simultaneous mutations, many occur-
ring at low frequency and unfortunately may not neatly divide
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